These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33224889)

  • 41. Complexes formed by mutant p53 and their roles in breast cancer.
    Bellazzo A; Sicari D; Valentino E; Del Sal G; Collavin L
    Breast Cancer (Dove Med Press); 2018; 10():101-112. PubMed ID: 29950894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of Prenylated Proteins, Autophagy Impairment and Apoptosis in SH-SY5Y Neuronal Cell Model of Mevalonate Kinase Deficiency.
    Tricarico PM; Romeo A; Gratton R; Crovella S; Celsi F
    Cell Physiol Biochem; 2017; 41(4):1649-1660. PubMed ID: 28359055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mutant p53/Hif1α/miR-30d axis reprograms the secretory pathway promoting the release of a prometastatic secretome.
    Capaci V; Mantovani F; Sal GD
    Cell Stress; 2020 Oct; 4(11):261-264. PubMed ID: 33150301
    [No Abstract]   [Full Text] [Related]  

  • 44. 25-Hydroxycholesterol and inflammation in Lovastatin-deregulated mevalonate pathway.
    Tricarico PM; Gratton R; Braga L; Celsi F; Crovella S
    Int J Biochem Cell Biol; 2017 Nov; 92():26-33. PubMed ID: 28918367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases.
    Jurczyluk J; Munoz MA; Skinner OP; Chai RC; Ali N; Palendira U; Quinn JM; Preston A; Tangye SG; Brown AJ; Argent E; Ziegler JB; Mehr S; Rogers MJ
    Immunol Cell Biol; 2016 Nov; 94(10):994-999. PubMed ID: 27377765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
    Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
    Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does prenylation predict progression in NAFLD?
    Ghorbani P; Smith TK; Fullerton MD
    J Pathol; 2019 Mar; 247(3):283-286. PubMed ID: 30374976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Farnesol-mediated shift in the metabolic origin of prenyl groups used for protein prenylation in plants.
    Huchelmann A; Brahim MS; Gerber E; Tritsch D; Bach TJ; Hemmerlin A
    Biochimie; 2016 Aug; 127():95-102. PubMed ID: 27138105
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes.
    Gloushankova N; Ossovskaya V; Vasiliev J; Chumakov P; Kopnin B
    Oncogene; 1997 Dec; 15(24):2985-9. PubMed ID: 9416842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
    Hasan WNW; Chin KY; Jolly JJ; Ghafar NA; Soelaiman IN
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):450-457. PubMed ID: 29683099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis.
    Singh RP; Kumar R; Kapur N
    J Environ Pathol Toxicol Oncol; 2003; 22(2):75-92. PubMed ID: 14533871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.
    Pereira M; Matuszewska K; Glogova A; Petrik J
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-cancer therapy: targeting the mevalonate pathway.
    Swanson KM; Hohl RJ
    Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosensor-assisted transcriptional regulator engineering for Methylobacterium extorquens AM1 to improve mevalonate synthesis by increasing the acetyl-CoA supply.
    Liang WF; Cui LY; Cui JY; Yu KW; Yang S; Wang TM; Guan CG; Zhang C; Xing XH
    Metab Eng; 2017 Jan; 39():159-168. PubMed ID: 27919791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
    Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
    Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
    [No Abstract]   [Full Text] [Related]  

  • 56. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
    Pfister NT; Prives C
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism.
    Vitale M; Di Matola T; Rossi G; Laezza C; Fenzi G; Bifulco M
    Endocrinology; 1999 Feb; 140(2):698-704. PubMed ID: 9927296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-prenylation-processing enzymes as new targets in oncogenesis.
    Winter-Vann AM; Casey PJ
    Nat Rev Cancer; 2005 May; 5(5):405-12. PubMed ID: 15864282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FBXW7 regulates endothelial barrier function by suppression of the cholesterol synthesis pathway and prenylation of RhoB.
    Pronk MCA; Majolée J; Loregger A; van Bezu JSM; Zelcer N; Hordijk PL; Kovačević I
    Mol Biol Cell; 2019 Mar; 30(5):607-621. PubMed ID: 30601691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.